Visualizing Vascular Mechanisms of Salt Sensitivity

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03696433
Collaborator
(none)
20
1
2
48
0.4

Study Details

Study Description

Brief Summary

This study aims to assess the salt sensitive blood pressure response to dietary salt load compared with radiological markers of salt handling.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Low-salt diet
  • Dietary Supplement: High-salt diet
N/A

Detailed Description

Hypertension is a major cause of heart disease, heart failure, and stroke. Hypertension, or high blood pressure, affects people differently and is related to the body's ability to maintain healthy circulation of salt. Some individuals may be affected by salt sensitive blood pressure (SSBP), when their blood pressure changes in response to dietary salt load. SSBP is a prevalent, independent risk factor for developing cardiovascular disease that preferentially affects black individuals. Current methods to assess SSBP require dietary salt loading over the course of days to weeks, and measurement of blood pressure following high salt diet and low salt diet. Such lengthy protocols are not feasible in a clinical setting to evaluate this risk factor for cardiovascular disease, and more importantly, these procedures provide incomplete information about mechanisms of salt sensitivity.

Our knowledge regarding salt handling in the body is limited. While renal dysfunction is partly responsible for SSBP, recent research points to the role of lymphatic vascular clearance in regulating tissue salt storage and blood pressure control. To better understand these mechanisms in vivo, we have recently developed a noninvasive magnetic resonance (MR) lymphangiography method sensitive to lymphatic vasculature, and applied standardized MR protocols for measuring tissue sodium and fat storage in adults with impaired lymphatic clearance. We found evidence of lymph stasis and tissue salt deposition that correlated with local subcutaneous fat volume. Here, we will test whether similar lymphatic pathways are impaired in persons with SSBP, leading to tissue salt and fat storage, in comparison to the involvement of renal dysfunction in SSBP tissue profiles.

The aims of this study are to improve our understanding of vascular mechanisms of human salt storage, and to provide standardized radiologic biomarkers sensitive to the SSBP phenotype. This study will test the primary hypothesis that the SSBP response is correlated with baseline tissue sodium storage, and elevated in persons with salt sensitivity. Secondary hypotheses will address whether the SSBP response is related to fat storage, lymphatic vascular function, renal vascular function, and impaired target organ responses to salt loading, including decreased urinary sodium excretion, and less suppression of plasma renin and serum aldosterone.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
Visualizing Vascular Mechanisms of Salt Sensitivity
Actual Study Start Date :
Feb 1, 2019
Anticipated Primary Completion Date :
Feb 1, 2023
Anticipated Study Completion Date :
Feb 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Low- then high-salt diet

10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: low-salt diet, then washout consisting of the subject's typical diet, then high-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.

Dietary Supplement: Low-salt diet
The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.

Dietary Supplement: High-salt diet
The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.

Experimental: High- then low-salt diet

10 subjects will be enrolled and each will undergo study procedures at 4 separate visits. Subjects will be randomly assigned to this study arm, differing in the order of low and high salt diets. After a baseline visit to include a noninvasive MRI scan, the subject will begin this study diet: high-salt diet, then washout consisting of the subject's typical diet, then low-salt diet. Each dietary or washout period lasts for 7 days, and study visits will occur after each period.

Dietary Supplement: Low-salt diet
The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.

Dietary Supplement: High-salt diet
The high-salt diet (7 days) consists of each subject's typical diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.

Outcome Measures

Primary Outcome Measures

  1. Change in Salt-sensitive blood pressure after low salt diet [Following completion of all dietary supplements and washout, in no less than 21 days.]

    Measured as the difference in mean arterial pressure following high-salt diet compared to low-salt diet

Secondary Outcome Measures

  1. Tissue sodium content of the legs [At baseline]

    Measured by sodium MRI

  2. Fat fraction of the legs [At baseline]

    Measured by conventional MRI, in units of fat/water volume ratio

  3. Kidney blood perfusion rate [At baseline]

    Measured by conventional noninvasive MRI

  4. Lymphatic stasis of the legs [At baseline]

    Measured by noninvasive MR lymphangiography

  5. Urinary sodium excretion [At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.]

    Measured from 24-hour urine collection

  6. Plasma renin [At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.]

    Physiological parameter

  7. Serum aldosterone [At baseline and each of 3 study visits occurring about every 7 days, to be completed in no less than 21 days.]

    Physiological parameter

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Identification as black race

  • Age between 18 and 55 years

  • Body mass index between 25 and <35 kg/m2

  • Normotensive or pre-hypertensive

  • Willing to adhere to study diets

  • Able to provide informed consent and communicate with study personnel

Exclusion Criteria:
  • Prevalent cardiovascular disease or use of medications for cardiovascular disease

  • Current or prior history of hypertension or use of blood pressure lowering medications

  • Current or prior history of diabetes mellitus or use of anti-diabetic medications

  • Prevalent renal disease (eGFR < 60 ml/min/1.73m2), abnormal serum sodium or potassium

  • Current or prior smoker

  • Current pregnancy, or use of hormone replacement therapy or oral contraceptive

  • Current steroid use

  • Contraindications to MRI

  • Active infection or open wounds on the top of the feet or hands

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vanderbilt University Medical Center Nashville Tennessee United States 37212

Sponsors and Collaborators

  • Vanderbilt University Medical Center

Investigators

  • Principal Investigator: Rachelle Crescenzi, PhD, Department of Radiology, Vanderbilt University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Rachelle Crescenzi, Research Instructor, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT03696433
Other Study ID Numbers:
  • 181610
First Posted:
Oct 4, 2018
Last Update Posted:
Feb 3, 2022
Last Verified:
Feb 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Rachelle Crescenzi, Research Instructor, Vanderbilt University Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 3, 2022